کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2998989 | 1180267 | 2010 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
American College of EndocrinologyLiraglutide Effect and Action in DiabetesACEPCPFDAGLP-1homeostasis model assessment of β-cell functionGIPFPGACCORDHbA1cDPP-4AACEPPGHOMA-β - HOMA-bUS Food and Drug Administration - اداره غذا و داروی ایالات متحدهAction to Control Cardiovascular Risk in Diabetes - اقدام برای کنترل خطر قلبی عروقی در دیابتAmerican Association of Clinical Endocrinologists - انجمن آمریکایی غدد و متابولیسم بالینیDiabetes mellitus - دیابت قندیdipeptidyl peptidase 4 - دیپپتیدیل پپتیداز 4Lead - سربadverse event - عارضه جانبی یا عوارض جانبیconfidence interval - فاصله اطمینانcardiovascular - قلبی عروقیFasting plasma glucose - قند خون ناشتاHemoglobin A1c - هموگلوبین A1cPrimary care physician - پزشک مراقبت اولیهglucagon-like peptide 1 - پپتید مشابه گلوکاگون 1Postprandial glucose - گلوکز پس از فروپاشیglucose-dependent insulinotropic polypeptide - گلیکول وابسته به پلی پپتید انسولینوتروپیک
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
The prevalence of type 2 diabetes mellitus (DM) is increasing substantially in the United States. Almost 24 million people have the disease, with most of these patients treated by primary care physicians. Optimal treatment of type 2 DM requires physicians to understand the pathophysiology of this disorder. Once the physiologic defects are determined, lifestyle interventions and glucoselowering medications can be prescribed to minimize the state of chronic hyperglycemia and to address the pathophysiologic defects associated with type 2 DM. Other metabolic abnormalities, including hyperlipidemia, hypertension, and oxidative stress, must also be addressed to reduce the patient's risk of cardiovascular disease. The incretin system plays a role in the pathogenesis of type 2 DM. Incretin-based therapies, including glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, have shown efficacy and safety in treating type 2 DM and have been reviewed in consensus treatment algorithms. This article provides an overview of the role of incretin-based therapies in the management of patients with type 2 DM and how primary care physicians can incorporate these agents into their practice.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 85, Issue 12, Supplement, December 2010, Pages S38-S49
Journal: Mayo Clinic Proceedings - Volume 85, Issue 12, Supplement, December 2010, Pages S38-S49
نویسندگان
Jeff MD,